TCM
EWTX icon

Tyro Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Tyro Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.9M Buy
+612,965
New +$21.1M 5.59% 11

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tyro Capital Management's EWTX Position: Q2 2026 in Review

Tyro Capital Management opened a new position in Edgewise Therapeutics (EWTX) in Q2 2026: 612,965 shares worth $24.9M. The stake represents 5.59% of the portfolio and ranks #11 among its holdings.

223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Tyro Capital Management held 612,965 shares of Edgewise Therapeutics worth $24.9M as of Q2 2026.
  • Edgewise Therapeutics was a new Tyro Capital Management position in Q2 2026.
  • Edgewise Therapeutics made up 5.59% of Tyro Capital Management's portfolio in Q2 2026, its #11 holding.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Tyro Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.